Dyax, Pfizer, Paul Capital Partners deal

Dyax sold its royalty stream from Pfizer's Xyntha recombinant Factor VIII to Paul Capital's Paul Capital Healthcare for $10 million in cash. Pfizer gained the hemophilia treatment through last year's...